Share on LinkedInShare on LinkedIn

ARTICLE · 24 FEBRUARY 2021

No Unpatentability In A Successful Motion To Amend

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Contributor
Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP is one of the world’s largest firms focusing on...

View firm profile
Explore more from Finnegan, Henderson, Farabow, Garrett & Dunner LLP

In Mylan Labs. Ltd. v. Aventis Pharma S.A., IPR2016-00712, Paper 112 (P.T.A.B. Oct. 22, 2019), aff'd without opinion (Fed. Cir. Jan. 15, 2021), the Patent Trial and Appeal Board granted Patent Owner's motion to amend, ...

United StatesIntellectual Property

Holding

In Mylan Labs. Ltd. v. Aventis Pharma S.A., IPR2016-00712, Paper 112 (P.T.A.B. Oct. 22, 2019), aff'd without opinion (Fed. Cir. Jan. 15, 2021), the Patent Trial and Appeal Board ("PTAB") granted Patent Owner's motion to amend, finding that Petitioner had not shown the proposed substitute claims to be unpatentable.

Background

The drug at issue was JEVTANA® (cabazitaxel), which is indicated for use in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer. Mylan challenged claims 1-5 and 7-30 of Orange Book-listed U.S. Pat. No. 8,927,592 ("the '592 patent") as unpatentable under 35 U.S.C. § 103(a). The '592 patent, along with two continuation patents that issued from it, moved the patent expiration date for JEVTANA® out about five years beyond the other Orange Book-listed patents. This can be seen from the present Orange Book report on cabazitaxel:

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from